Sdccgsbi-0050283.P002

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: Sdccgsbi-0050283.P002
• 英文别名: 2-carboxy-5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-oxonioethyl]amino]propyl]-1,3-benzodioxole-2-carboxylate
• 化学式: C20H20ClNO7
• 分子量: 421.8
• InChiKey: JEDJMKTVUPSHFW-ABAIWWIYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  125
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders
  申请人：Fraser Oliver Matthew

  公开号：US20050113421A1

  公开（公告）日：2005-05-26

  A method is provided for using Cav2.2 subunit calcium channel modulators, particularly thiazolidinone, oxazolidinone, and imidazolone derivatives, to treat non-inflammatory gastrointestinal tract disorders.

  提供了一种方法，用于使用Cav2.2亚单位钙通道调节剂，特别是噻唑啉酮、噁唑啉酮和咪唑啉酮衍生物，来治疗非炎症性胃肠道疾病。
• Indole compounds as B3 androceptor agonist
  申请人：Miyoshi Shiro

  公开号：US20080076815A1

  公开（公告）日：2008-03-27

  Compounds of the general formula (I): or a salt thereof, wherein R 1 is a hydrogen atom or the like; R 2 is NHSO 2 R 3 or the like; R 3 is a (C 1 -C 6 )alkyl group or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 may be the same or different and are each independently a hydrogen atom or the like; X is an oxygen atom or the like; Y is an oxygen atom or the like; Z 1 to Z 6 are a carbon atom or the like; n is an integer of 0 to 6; *1 is an asymmetric carbon atom; and *2 is an asymmetric carbon atom when R 5 is other than a hydrogen atom.

  通式(I)的化合物或其盐，其中R1是氢原子或类似物；R2是NHSO2R3或类似物；R3是(C1-C6)烷基或类似物；R5是氢原子或类似物；R6和R7可以相同或不同，且各自独立地是氢原子或类似物；X是氧原子或类似物；Y是氧原子或类似物；Z1至Z6是碳原子或类似物；n是0到6的整数；*1是不对称碳原子；当R5不是氢原子时，*2是不对称碳原子。
• Kinin antagonists for treating bladder dysfunction
  申请人：Jerini AG

  公开号：EP1741444A1

  公开（公告）日：2007-01-10

  The present invention is related to the use of a kinin receptor antagonist for the manufacture of a medicament for the treatment and/or prevention of bladder dysfunction, whereby the kinin receptor is selected from the group comprising B1 and B2 receptors.

  本发明涉及使用激肽受体拮抗剂制造治疗和/或预防膀胱功能障碍的药物，其中激肽受体选自包括 B1 和 B2 受体的组。
• Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
  申请人：Dynogen Pharmaceuticals, Inc.

  公开号：EP1721607A1

  公开（公告）日：2006-11-15

  A method is provided for using α2δ subunit calcium channel modulators or other compounds that interact with the α2δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α2δ subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

  本发明提供了一种使用α2δ亚基钙通道调节剂或其他与α2δ钙通道亚基相互作用的化合物与一种或多种具有平滑肌调节作用的化合物联合治疗和/或缓解正常人和脊髓损伤患者疼痛性和非疼痛性下尿路障碍相关症状的方法。根据本发明，α2δ亚基钙通道调节剂包括 GABA 类似物（如加巴喷丁和普瑞巴林）、加巴喷丁的融合双环或三环氨基酸类似物以及氨基酸化合物。具有平滑肌调节作用的化合物包括抗心绞痛药、β3 肾上腺素能激动剂、解痉药、神经激肽受体拮抗剂、缓激肽受体拮抗剂和一氧化氮供体。
• Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
  申请人：Boehringer Ingelheim Pharma GmbH & Co.KG

  公开号：EP1769792A1

  公开（公告）日：2007-04-04

  Diese Erfindung betrifft die Verwendung von beta-3-Adrenozeptor-Agonisten zur Vorbeugung und Behandlung von Nierenschäden und / oder funktionalen Blasenbeschwerden, insbesondere von Blasenbeschwerden neurogenen Ursprungs in Folge von Rückenmarksschädigungen.

  本发明涉及使用β-3肾上腺素受体激动剂预防和治疗肾损伤和/或功能性膀胱问题，特别是脊髓损伤导致的神经源性膀胱问题。